Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Laekna Starts China-US Trials of AKT Kinase Inhibitor for Breast Cancer

publication date: May 26, 2022

Laekna Therapeutics, a Shanghai-New Jersey clinical-stage biotech, has dosed the first patients in a China-US Phase Ib/III trial of an AKT kinase inhibitor for breast cancer. Afuresertib, an investigational AKT kinase inhibitor, will be administered as a second-line therapy to patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Laekna in-licensed global rights to afuresertib from Novartis. One week ago, Laekna raised $61 million in a Series D financing to advance its next-gen cancer and liver disease medicines. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
September 13-16, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022